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Despite the great strides made in coronary revascularization
(or possibly because of these), there remains a patient
population experiencing anginal symptoms who are not
considered candidates for either coronary artery bypass graft
surgery (CABG) or percutaneous transluminal coronary
angioplasty (PTCA). Most have had one or more attempts
at traditional revascularization, although some have diffusely
diseased distal vessels precluding these forms of therapy.
Although one would have at first thought that the number
of such “nonrevascularizable” patients to be small, this does
not appear to be the case. Furthermore, the frustration
associated with the management of such patients serves to
underscore the magnitude of this condition. The clinical
spectrum of these patients varies markedly. Most have
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chronic angina that is relatively stable, but may be incapac-
itating. Others are unstable and may experience difficulty in
being weaned from parenteral medication. Some have
triple-vessel disease and a large amount of myocardium at
risk; others have only a small region served by a single vessel.
Some have poor left ventricular function, while others have
no contractile impairment. Some are taking many medica-
tions; others have difficulty tolerating even small amounts of
antianginal drugs. The need for alternative approaches to
the care of these patients is clear. The goals of such therapy
would be to enhance the quality of life and reduce the
morbidity and perhaps mortality associated with coronary
disease. The paradigm for achieving these outcomes is to
reduce ischemia by favorably influencing coronary perfusion
or myocardial demand. A number of novel techniques,
presently in various stages of development, have been
suggested to address this need. One of the most intriguing
is transmyocardial laser revascularization (TMR).
Transmyocardial revascularization. It is ironic that the
left ventricle, which is literally bathed in oxygenated blood,
has as its most common affliction, ischemia. Not surpris-
ingly, efforts have been extended to more directly perfuse
myocardium from blood within the left ventricle when the
coronary artery supply is compromised. Initial enthusiasm to
employ a laser probe to create transmural tunnels was based
on the presumption that the tunnels would remain patent
and, in a fashion, mimic the ventricular sinusoids of the
reptilian heart. Despite the early controversy surrounding
the long-term patency of these laser tracts (1), most inves-
tigators now agree that the channels occlude soon after their
creation and there is no direct camerosinusoidal blood flow
long term (2–4).
The lack of substantive anatomic or angiographic evi-
dence of “revascularization” would have doomed TMR long
ago had it not been for a surprisingly high rate of clinical
success. A worldwide registry of over 3,000 patients re-
ported a decrease in anginal class in 80%, with 30% having
no angina at one-year follow-up (5). These results are quite
remarkable in that the typical patient undergoing TMR has
Canadian Cardiovascular Society (CCS) class III or IV
angina, has had one or more bypass surgeries or angioplas-
ties, or both, is taking multiple medications for ischemic
heart disease and is not considered a candidate for tradi-
tional revascularization. True, angina is a subjective com-
plaint and it is difficult to exclude a powerful placebo effect
when “laser” and “surgery” are combined. Although patients
often have a modest increase in exercise tolerance after
treatment, there have not been the dramatic improvements
in perfusion scanning that accompany traditional revascu-
larization. Yet pain relief is sustained in many, and there is
a suggestion of an improvement in ischemic threshold by
dobutamine stress echocardiography (6) as well as some
reports of increased perfusion on radionuclide (7) and
positron emission tomographic scanning (8).
Pathophysiology of TMR. Accepting the fact that the
channels produced by the laser probe do not remain patent,
alternative mechanisms to explain the clinical efficacy
achieved by TMR have been explored. Animal studies lend
support to two not mutually incompatible hypotheses—
angiogenesis and sympathetic denervation. The injury pro-
duced by the laser energy results in the elaboration of
vascular growth factors that stimulate angiogenesis (9).
Histologic confirmation of neovascularity in ischemic myo-
cardium after TMR is impressive (10). It appears, however,
that this response is not specific for laser injury in that a
power drill (11), needle (12) and radiofrequency ablation
system (13) have all produced similar results. Some inves-
tigators suggest, however, that laser energy per se may be an
important factor in the neovascularization process (14).
Allowing for the moment that there is an advantage to
laser-induced TMR, is there a difference between the types
of laser employed? Although there appears to be some
variation in the histopathology produced, the primary dis-
tinguishing characteristic between lasers is the inability of
the carbon dioxide system to transmit energy through
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optical fibers. This limits the use of this device to direct
application to the heart by thoracotomy. Other laser types
(e.g., holmium, excimer) employ fiberoptic catheters that
are capable of being delivered to the epicardium through an
endoscope (15) or intravascularly, through a guide catheter
to the endocardium (16).
The dark side of TMR. The clinical efficacy of TMR is
achieved at some cost. Initial reports cited an operative
mortality of about 10%, with an incidence of death at 1 year
being ;20% (17,18). Overall morbidity of the operative
procedure is also high, with an incidence of myocardial
infarction of 19%, cardiac ischemia of 52% and noncardiac
morbidity of 35% (19,20). Patients with acute coronary
syndromes and those with poor ventricular function appear
to be at greatest risk. Support of the latter using intraaortic
balloon counterpulsation may be beneficial (21); however, it
should be noted that unlike CABG or PTCA, there is no
immediate revascularization afforded by TMR. Any increase
in perfusion probably takes weeks to occur as the process of
angiogenesis evolves.
It is likely that much of the mortality and morbidity
associated with TMR is related to a learning curve during
which both technical expertise and case selection are refined.
Procedural mortality rates ,5% are now commonly being
reported (22–24). Although the process of lasing channels
through the heart appears to produce little acute or chronic
myocardial damage, the risk of thoracotomy alone is signif-
icant in this patient group.
Controlled trials of TMR. In view of the discrepancy
between symptomatic improvement and objective evidence
of increased perfusion to ischemic regions, controversy
surrounds the risk-benefit ratio of TMR. It has been
assumed that randomized, controlled trials would establish
the clinical utility of this form of therapy. March (23)
reported the results of a study in which 198 patients were
randomized to TMR or continued medical management.
This multicenter investigation demonstrated an improved
anginal class, a decrease in reversible perfusion defects on
dipyridamole stress thallium SPECT study and a marked
decrease in the occurrence of unstable angina over 12 months
of follow-up. Sixty percent of patients randomized to
medical therapy crossed over to TMR. In contradistinction
to this study, Schofield et al. (24) reported a less satisfying
experience. Although anginal class was significantly im-
proved by TMR as compared with medical therapy at
12 months, differences in objective exercise performance
were not impressive. There was no benefit to TMR on fixed
or reversible ischemic sites revealed by sestamibi study. The
operative mortality rate was 5%, and the survival rate at
one year was 89% in the TMR group versus 96% in the
medically treated patients. The authors conclude that adop-
tion of TMR cannot be advocated. In an accompanying
commentary to this paper, Pretre and Turina (25) empha-
size a conservative view toward the use of the laser,
characterizing it as “an expensive analgesic device.”
Percutaneous myocardial revascularization. Although
TMR might lend itself to combined procedures in which
traditional bypass (26), minimally invasive bypass (27)
and/or valve surgery (28) is performed, the morbidity and
mortality accompanying it as a stand-alone procedure are
major obstacles to its use. Much of this risk appears related
to thoracotomy, however, and may be obviated by a percu-
taneous approach. Kim et al. (29) demonstrated the feasi-
bility of creating myocardial channels from the endocardial
surface of the left ventricle using a catheter system intro-
duced through the femoral artery. The methodology al-
lowed for all segments of the left ventricle to be accessed by
the laser under fluoroscopic guidance. Care was taken in
catheter design and employment to avoid “through and
through” perforation of the myocardium, as thought neces-
sary with the epicardial approach.
In addition to reducing the morbidity and mortality
associated with thoracotomy, percutaneous transmyocardial
revascularization (also called direct myocardial revascular-
ization [DMR]) theoretically provides access to portions of
the left ventricle (i.e., septum) not easily approached from
the epicardium. A limitation of the percutaneous approach,
however, is the difficulty of reproducing the carefully spaced
matrix of entry sites in the ischemic region with the
precision afforded by direct observation. The introduction of
a nonfluoroscopic catheter navigation system may improve
the operator’s ability to reach a target region and more
precisely locate and then tag the sites that are lased (30).
The present study. Lauer et al. (31), in this issue of JACC,
presents procedural and follow-up data of 34 patients
undergoing percutaneous laser TMR. A mean of 10.4 laser
channels per ischemic region was created; all but seven
patients had only one region treated. There was no peripro-
cedural mortality and surprisingly little morbidity. Six pa-
tients developed small pericardial effusions within 24 h of
the procedure, none required drainage and all spontaneously
resolved. Over a six-month follow-up period the CCS
anginal class decreased from a mean of 3.1 to 1.3, and
bicycle exercise duration increased from a mean of 384 to
514 s. There was, however, no improvement in perfusion
detected by radionuclide scanning. Since the submission of
this report, a great deal of clinical experience with DMR has
accumulated. Shawl et al. (32), using a slightly different
holmium DMR system, demonstrated similar safety and
antianginal efficacy in a small group of patients. Preliminary
results of a trial in which 221 patients were randomized to
DMR versus medical therapy were recently presented (33).
Those randomized to DMR experienced a marked improve-
ment in anginal class, which was sustained over the six-
month follow-up period. There was no procedural mortal-
ity, pericardial tamponade or ventricular fibrillation,
emphasizing the relative safety of this form of therapy.
Although the efficacy of the percutaneous procedure
seems roughly comparable to that of TMR, it is of interest
to note that the number of channels made with the former
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is typically about one-half of that reported with the latter.
One might assume that the channel “density” per ischemic
region would have some influence on the ultimate results
achieved, and further research is necessary to clarify this
point.
Laser revascularization today. Transmyocardial laser re-
vascularization has been approved by the Food and Drug
Administration for treatment of chronic stable angina in
patients with class III and IV symptomatology in whom
conventional revascularization cannot be performed. A va-
riety of percutaneous systems are in various stages of the
regulatory evaluation. Combining the laser procedures with
more traditional forms of revascularization (CABG and
PTCA) is being studied. Despite the rather remarkable and
sustained nature of the symptomatic improvement encoun-
tered with TMR and DMR, objective confirmation of
improved myocardial perfusion has been inconsistent, and
objectively assessed increases in exercise tolerance have been
modest. Although randomized studies appear to confirm
the results of the pilot and registry experience, the potential
of a dramatic placebo effect cannot be discarded. Skeptics
will remind us of other experiences with expensive cardio-
vascular procedures that have not stood the test of time.
We must learn more about the pathophysiology of TMR.
If denervation is the primary effect, do we need to be
concerned about asymptomatic ischemia? Is there an effect
of the procedure that might promote atherosclerotic pro-
gression? Assuming that the safety and efficacy of DMR is
confirmed, it seems likely that this will be the favored
approach to patients with ischemic territories that cannot be
revascularized by conventional means. So TMR will be
reserved for patients undergoing other procedures requiring
thoracotomy.
Both procedures will be extended far beyond the current
indication for TMR. For instance, patients undergoing
conventional CABG or PTCA might have TMR or DMR
performed in the same zone to protect against recurrent
ischemia should the bypass fail or angioplasty site restenose.
Interventional cardiologists may wish to extend the role of
percutaneous intervention by using DMR for regions served
by “nonangioplastiable” vessels, even if such vessels were
suitable for bypass. For example, a patient might have
angioplasty and stenting of an ideal lesion in the left anterior
descending coronary artery and DMR to the region served
by a chronically occluded right coronary artery instead of
double-vessel bypass surgery. It will be important to study
such applications carefully before assuming their safety and
effectiveness.
Expectations for the future. It is natural that other mech-
anisms capable of creating myocardial channels (mechanical
drill, radiofrequency energy, ultrasound) be vigorously pur-
sued. Assuming the mechanism of laser myocardial revas-
cularization is the induction of nonspecific tissue injury, one
or more of these devices may be less expensive alternatives to
the laser treatment. If angiogenesis is the mechanism of pain
relief, exploration of approaches to maximize neovascular-
ization is needed. There is currently great enthusiasm for
gene therapy as a stimulus for angiogenesis. Direct in-
tramyocardial gene transfer has been shown to stimulate
angiogenesis (34). Sayeed-Shah et al. (35) have suggested
that transfection efficiency of plasmid vascular endothelial
growth factor is increased with the concomitant use of
TMR. Percutaneous intramyocardial delivery of replication-
deficient adenovirus has been demonstrated (36). Clinical
trials combining a percutaneous myocardial “channel-
making” technology and the insertion of a cytokine or
genetic material will begin soon.
Conclusions. Although the mechanism of the symptom-
atic relief afforded by TMR remains uncertain, it would
appear to be a reasonable approach to the patient with
refractory symptoms who is not considered a candidate for
conventional revascularization. At best, the procedure re-
lieves symptoms by inducing neovascularization that is
capable of reducing but not eliminating ischemia caused by
disease of the epicardial arteries. At worst, the procedure
denervates angina-producing regions of the heart and may
or may not have a beneficial physiologic effect accompany-
ing the analgesia. In assessing the ultimate role of TMR and
DMR, the value of alternative “nonrevascularizing” non-
pharmacologic therapies such as spinal cord stimulation
(37), transcutaneous electrical nerve stimulation (38) and
external counterpulsation (39) must also be considered.
There may, in fact, be a light at the end of the tunnel for
patients with nonrevascularizable angina.
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